Ads
related to: primary care vaksin
Search results
Results From The WOW.Com Content Network
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ), the virus that causes coronavirus disease 2019 ( COVID‑19 ). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing ...
COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, Mainland China in December 2019 [4] and was confirmed to have spread to Indonesia on 2 March 2020. [5] COVID-19 vaccination in Indonesia will cover more than 75% of overall Indonesian population ...
The COVID-19 Immunisation Task Force, or CITF (Malay: Jawatankuasa Petugas Khas Imunisasi COVID-19 ), is a committee that was established based on the decision made during a cabinet meeting held on 20 January 2021 by the Government of Malaysia to ensure that the vaccines' distribution is done flawlessly.
Primary health care ( PHC) is "essential health care " that is based on scientifically sound and socially acceptable methods and technology. This makes universal health care accessible to all individuals and families in a community. PHC initiatives allow for the full participation of community members in implementation and decision making. [1]
Vaccine production has several stages. First, the antigen itself is generated. Viruses are grown either on primary cells such as chicken eggs (e.g., for influenza) or on continuous cell lines such as cultured human cells (e.g., for hepatitis A). Bacteria are grown in bioreactors (e.g., Haemophilus influenzae type b). Likewise, a recombinant ...
CoronaVac, also known as the Sinovac COVID-19 vaccine, [3] is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. [4] [5] It was phase III clinically trialled in Brazil, [6] Chile, [7] Indonesia, [8] the Philippines, [9] and Turkey [10] and relies on traditional technology similar to other inactivated ...
In June 2021, a primary Novavax-funded study found that the vaccine has an overall efficacy of 83.4% two weeks after the first dose and 89.7% one week after the second dose. A post hoc analysis showed an efficacy of 86.3% against the B.1.1.7 (Alpha) variant and 96.4% against "non-B.1.1.7 strains", the majority of which were the "prototype ...
Japan has so far approved Pfizer–BioNTech, Moderna and Oxford–AstraZeneca for use. In April 2024, data from the government shows that 79.5% of people have had their second dose, while 80.4% have received first shot. [7] Today, 79 percent of Japanese people have received two doses of a COVID-19 vaccine; 67 percent have received a third ...
Ads
related to: primary care vaksin